Abstract
Purpose.
To evaluate the change in vision after 3 monthly consecutive intravitreal injections of 1.25 mg of bevacizumab for neovascular age-related macular degeneration (AMD).
Methods.
A retrospective analysis of 35 eyes was performed. Visual acuity (VA) at initial visit and at each follow-up visit was compared. The injection of bevacizumab was performed at 30-day intervals and patients were observed for 5 months after the last injection.
Results.
Of the 35 eyes, 9 had received previous treatment with photodynamic therapy with or without 4 mg of intravitreal triamcinolone. VA was measured in Snellen table and transformed into logMAR for statistical purposes. Mean age was 76.66 years (range, 49–90 years). There were 24 (69%) women and 11 (31%) men. Mean VA at the initial visit was 0.92±0.50. At month 1, mean VA was 0.84±0.51 and at month 2 was 0.74±0.51. At month 3, mean VA remained 0.74±0.49. Six and 8 months after the initial visit, VA was 0.79±0.49 and 0.77±0.50, respectively. The improvement in VA was statistically significant at month 2 and at the end of the follow-up (8 months) compared with the baseline VA.
Conclusions.
Three consecutive monthly injections of intravitreal bevacizumab to treat neovascular AMD is effective in improving VA in the short term. Longer prospective studies should be performed to confirm VA stability after the third injection.
Get full access to this article
View all access options for this article.